Showing 7601-7610 of 8546 results for "".
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s
- Agenda Set for 2013 Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20130830-agenda_set_for_2013_cosmetic_surgery_forum/2459471/The 2013 Cosmetic Surgery Forum, taking place from December 5 – 7 at the Aria Resort and Casino in Las Vegas, has recently unveiled its agenda. According to course director Joel Schlessinger, MD, this year's meeting promises offer attendees a host of new sessions on injectables and newer methods of
- Roche's Erivedge OK'd in Canadahttps://practicaldermatology.com/news/20130827-roches_erivedge_okd_in_canada/2459474/Erivedge (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
- Psoriasis Foundation Urges CMS to Halt Proposed Cuts to Phototherapy Reimbursementhttps://practicaldermatology.com/news/20130815-psoriasis_foundation_urges_cms_to_halt_proposed_cuts_to_phototherapy_reimbursement/2459477/The National Psoriasis Foundation has stepped up efforts to halt the Centers for Medicare and Medicaid Services (CMS) plan to cut reimbursement rates to phototherapy in the proposed CY 2014 Medicare Physician Fee Schedule (PFS). According to the Foundation, if the proposed cuts pass, many physicians
- Live Cosmetic Surgery Workshop This Septemberhttps://practicaldermatology.com/news/20130812-live_cosmetic_surgery_workshop_this_september/2459480/Dr. Joe Niamtu, III will present the 2013 Ultimate Facial Rejuvenation Live Cosmetic Surgery Workshop September 20-22. The course will include lectures and live surgeries on:facelift and facial liposuction, browlift, eyelid surgery, facial implants, laser resurfacing, chemical peels, fillers, mole r
- AARS Hosting Acne and Rosacea Bootcamp September 6-8, 2013https://practicaldermatology.com/news/20130809-aars_hosting_acne_and_rosacea_bootcamp_september_6-8_2013/2459481/The American Acne and Rosacea Society (AARS) is hosting the Acne and Rosacea Bootcamp, a two-day CME event open to all medical health professionals involved in the management of acne and rosacea. The program will be held September 6-8, 2013 at the Hyatt Chicago Magnificent Mile. This event will p
- Differin Gel Found Effective in Adult Women with Acnehttps://practicaldermatology.com/news/20130807-differin_gel_found_effective_in_adult_women_with_acne/2459483/At the recent AAD Summer Meeting in New York, Galderma Laboratories presented results showing that Differin® (adapalene) Gel, 0.3% is efficacious in reducing acne lesions in adult women, and has been proven superior in reducing inflammatory lesions in women compared with vehicle gel. Investigators u
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu